SCHEMBL2948739

SCHEMBL2948739

N#Cc1ccc2oc(C(=O)Nc3ccc(Cl)cn3)c(N)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ TMPRSS4 Q9NRS4 1/20 0.49
▸ KDM4E B2RXH2 4/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ RAB9A P51151 3/20 0.47
▸ NFKB1 P19838 2/20 0.47
▸ NFKB2 Q00653 2/20 0.47
▸ RELA Q04206 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ALDH1A1 P00352 5/20 0.47
▸ HPGD P15428 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ F10 P00742 3/20 0.46
▸ HSD17B10 Q99714 1/20 0.44
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ SIRT2 Q8IXJ6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13515796 0.88 SMN1; SMN2 (0.61) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2951090 0.85 SMN1; SMN2 (0.57) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL13665190 0.84 SMN1; SMN2 (0.62) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL13665191 0.84 SORT1 (0.57) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2941972 0.83 SMN1; SMN2 (0.55) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL13665206 0.81 RAB9A (0.63) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2945692 0.81 SMN1; SMN2 (0.74) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2950349 0.80 SMN1; SMN2 (0.53) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2945609 0.80 SMN1; SMN2 (0.57) SMN1; SMN2KDM4ENPC1RAB9ANFKB1
SCHEMBL2942487 0.80 SMN1; SMN2 (0.54) SMN1; SMN2KDM4ENPC1RAB9ANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1489078-B1 BENZOFURAN DERIVATIVE MITSUBISHI TANABE PHARMA CORP (JP) 2010-01-06 — — EP disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 — — US disclosed
US-7531537-B2 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-05-12 — — US disclosed
CN-100439351-C Benzofuran derivative TANABE SEIYAKU CO (JP) 2008-12-03 — — CN disclosed
CN-100430392-C Carbamoyl-type benzofuran derivatives TANABE SEIYAKU CO (JP) 2008-11-05 — — CN disclosed
US-20060247273-A1 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-11-02 — — US disclosed
CN-1856488-A Carbamoyl-type benzofuran derivatives TANABE SEIYAKU CO (JP) 2006-11-01 — — CN disclosed
EP-1666478-A1 CARBAMOYL-TYPE BENZOFURAN DERIVATIVES TANABE SEIYAKU CO., LTD. (JP) 2006-06-07 — — EP disclosed
US-20050282808-A1 Benzofuran derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-22 — — US disclosed
CN-1656086-A Benzofuran derivative TANABE SEIYAKU CO (JP) 2005-08-17 — — CN disclosed
EP-1489078-A1 BENZOFURAN DERIVATIVE Tanabe Seiyaku Co., Ltd. (JP) 2004-12-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282808-A1 Benzofuran derivative F12, F2, F11 SMN1; SMN2 3151/4885TMPRSS4 1209/4885KDM4E 1427/4885
US-20060247273-A1 Carbamoyl-type benzofuran derivatives F12, F2, F3 SMN1; SMN2 4587/4885TMPRSS4 592/4885KDM4E 204/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 SMN1; SMN2 3067/4885TMPRSS4 1148/4885KDM4E 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback